Search

Displaying results 2371 - 2380 of 7540 in total
  1. Drug

    Acetazolamide

    go.drugbank.com/drugs/DB00819
    ApprovedInvestigationalVet approved

    Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition

    Synonyms: N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]acetamide, N-[5-(aminosulfonyl)-1,3,5-thiadiazol-2-yl]acetamide
  2. Drug

    Succimer

    go.drugbank.com/drugs/DB00566
    ApprovedInvestigational

    A mercaptodicarboxylic acid used as an antidote to heavy metal poisoning because it forms strong chelates with them.

  3. Drug

    Bromus secalinus pollen

    go.drugbank.com/drugs/DB10836
    Approved

    Bromus secalinus pollen is the pollen of the Bromus secalinus plant. Bromus secalinus pollen is mainly used in allergenic testing.

    Mixtures: Mixture of Twenty-Two Standardized and Non-Standardized GrassesCategories: Non-Standardized Pollen Allergenic Extract
  4. Drug

    Aminolevulinic acid

    go.drugbank.com/drugs/DB00855
    ApprovedInvestigational

    A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem]

  5. Drug

    Anagrelide

    go.drugbank.com/drugs/DB00261
    ApprovedInvestigational

    Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. … [A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated.[A214274]

  6. Drug

    Dalfampridine

    go.drugbank.com/drugs/DB06637
    ApprovedInvestigational

    FDA approved on January 22, 2010. … Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients.

  7. Drug

    Adenosine phosphate

    go.drugbank.com/drugs/DB00131
    ApprovedInvestigationalNutraceuticalWithdrawn

    Adenosine phosphate was withdrawn by the FDA since it was considered neither safe nor effective for its intended uses as a vasodilator and an anti-inflammatory.[L43937] … Adenosine phosphate, or adenylic acid, is an adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position.

    Synonyms: 5'-O-Phosphonoadenosine
  8. Drug

    Dasatinib

    go.drugbank.com/drugs/DB01254
    ApprovedInvestigational

    [A2226] The use of dasatinib was first approved by the FDA in 2006.[L45171,L45186] … [A2226,A11377] Also, mutations in the kinase domain of BCR-ABL may lead to relapse during imatinib treatment.

    Synonyms: N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
  9. Drug

    Tabelecleucel

    go.drugbank.com/drugs/DB17072
    ApprovedInvestigational

    It is produced by mixing T-cells with B-cells that have been infected with the Epstein-Barr virus (EBV). … own infected B-cells, thereby helping to control this condition.

  10. Drug

    Duvelisib

    go.drugbank.com/drugs/DB11952
    ApprovedInvestigational

    [A39025] Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018.[L4585] … Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma